Roche has signed a definitive merger agreement to acquire Anadys Pharmaceuticals, a manufacturer of antiviral drug compunds, for a total cash consideration of approximately $230m.
As per the merger agreement, Roche will acquire all the outstanding shares of Anadys’ common stock at a price of $3.70 per share in cash.
Anadys president and CEO Steve Worland said Roche’s capabilities and experience in HCV would provide the best chance of success for the new potential treatments to reach hepatitis C patients.
Roche Pharma Research and Early Development global head Jean-Jacques said the aim of this transaction is to offer physicians and hepatitis patients a powerful combination of therapies that bring them closer to a cure, even without the use of interferon.
"Anadys’ compounds provide additional modes of action that could lead to interferon-free treatment regimens without viral resistance," Jacques added.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData